Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Current Assets (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Current Assets data on record, last reported at $534.7 million in Q4 2025.

  • For Q4 2025, Current Assets fell 28.44% year-over-year to $534.7 million; the TTM value through Dec 2025 reached $534.7 million, down 28.44%, while the annual FY2025 figure was $534.7 million, 28.44% down from the prior year.
  • Current Assets reached $534.7 million in Q4 2025 per CLDX's latest filing, down from $604.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $835.3 million in Q1 2024 and bottomed at $167.6 million in Q2 2021.
  • Average Current Assets over 5 years is $474.2 million, with a median of $418.7 million recorded in 2021.
  • Peak YoY movement for Current Assets: soared 224.58% in 2021, then fell 28.44% in 2025.
  • A 5-year view of Current Assets shows it stood at $410.8 million in 2021, then fell by 22.67% to $317.7 million in 2022, then skyrocketed by 35.88% to $431.7 million in 2023, then soared by 73.08% to $747.2 million in 2024, then dropped by 28.44% to $534.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $534.7 million in Q4 2025, $604.3 million in Q3 2025, and $648.4 million in Q2 2025.